Search the Newsreel

Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from Analysts

Caribou Biosciences (NASDAQ:CRBU) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $7.75. The company's shares recently traded down 2.2% to $1.57. Caribou Biosciences reported a narrower-than-expected quarterly loss but missed revenue estimates, and institutional investors own …

Caribou Biosciences earnings beat by $0.07, revenue topped estimates

Caribou Biosciences (NASDAQ: CRBU) reported second-quarter EPS of $-0.240, beating analyst estimates by $0.07, and revenue of $2.65 million, surpassing the consensus estimate of $2.3 million. Despite the earnings beat, the company's stock price has declined by -24.770% in the last three months and …

RPG Life Sciences accepts Deepak Shukla's resignation as API head

Satellos Bioscience (MSLE) enters $50M at-the-market share deal

RPG Life Sciences completes API business transfer to subsidiary

Kingfa Science net profit up 111% in Q1FY27 to ₹802 crore

Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.78, Implies 122% Upside

Satellos Bioscience Inc.'s average 12-month price target has been adjusted to $21.78, down from $22.04, according to estimates from 6 analysts. This new target suggests a potential upside of approximately 122% from the August 13 closing price. The consensus rating among 7 covering analysts …

Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A

Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership in Alto Neuroscience, Inc., totaling 785,000 shares. These shares are held through a fund and a managed account advised by Vestal Point Capital, with both shared …

Core Scientific (CORZ): Jericho Capital and Josh Resnick disclose 7.2% ownership stake

Jericho Capital Asset Management L.P. and Josh Resnick have reported a joint beneficial ownership of 22,882,942 shares of Core Scientific, Inc. common stock, which represents 7.2% of the class. They share both voting and dispositive power over these shares. This disclosure was made via …

Pentwater Capital (NASDAQ: CORZ) discloses 1.34M-share Core Scientific position

Pentwater Capital Management LP and Matthew Halbower have disclosed a beneficial ownership of 1,336,594 shares of Core Scientific, Inc. common stock, representing 0.4% of the company's outstanding shares. This includes 800,000 shares issuable upon the exercise of options. All voting and dispositive authority over …

Achieve Life Sciences (ACHV) launches $150M at-the-market stock program

Achieve Life Sciences (ACHV) has established a $150 million at-the-market (ATM) equity offering program with Jefferies LLC as the sales agent. The company plans to sell common stock periodically, with net proceeds intended for the commercialization of cytisinicline, funding a Phase 3 clinical trial …

Sight Sciences (SGHT) insider plans 48,000-share stock sale after option exercise

Jeremy Hayden, an insider at Sight Sciences (SGHT), filed a Form 144 indicating his intent to sell 48,000 shares of common stock on August 14, 2026, following a stock option exercise. The planned sale has an aggregate market value of $395,878.84. This filing also …

Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing

Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole …

Cellectar Biosciences (CLRB): Caligan Partners reports 5.9% ownership stake

Caligan Partners LP and David Johnson have reported a beneficial ownership stake of 5.9% in Cellectar Biosciences (CLRB), amounting to 469,998 shares. This ownership is held through Caligan-managed funds and accounts, with shared voting and dispositive power. The percentage is based on 7,991,812 shares …

Senti Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Senti Biosciences Holdings, Inc. reported its earnings results for the second quarter and six months ended June 30, 2026. For the second quarter, the company's net loss decreased to USD 12.75 million from USD 14.73 million a year prior, with basic and diluted loss …

CORZ Stock Forecast & Analyst Ratings - August 2026

Why (ASMB) Price Action Is Critical for Tactical Trading

This article analyzes the price action of Assembly Biosciences Inc. (ASMB), highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis to …

Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants

Baker Bros. Advisors and its related entities have disclosed a 5.2% beneficial ownership stake in IDEAYA Biosciences, Inc. (IDYA), totaling 5,010,030 shares based on 96,375,637 shares outstanding as of June 30, 2026. The firm also holds prefunded warrants with a low exercise price but …

ARK reports 9.59% stake in Pacific Biosciences (PACB)

ARK Investment Management LLC and Catherine D. Wood have reported a beneficial ownership of 9.59% in Pacific Biosciences of California, Inc. (PACB), amounting to 29,781,416 shares. This disclosure, made via a SCHEDULE 13G/A filing, details their sole and shared voting and dispositive powers over …

Gilead Sciences (GILD) Could Be 8% Overvalued As AI Deal And Q2 Results Lift Shares

Gilead Sciences (GILD) is gaining investor attention due to a new AI collaboration with Nucleai and positive Q2 results, though some analyses suggest it might be overvalued by about 8%. The company is transitioning into a multi-platform biopharma, but differing valuation models present varied …

Assembly Biosciences (NASDAQ:ASMB) Trading Up 8.2% on Strong Earnings

Assembly Biosciences (NASDAQ:ASMB) saw its shares rise by 8.2% after reporting better-than-expected quarterly earnings, with a loss of $0.20 per share against an anticipated $0.72 loss and revenue of $13.37 million surpassing estimates of $8.60 million. Analysts have a "Moderate Buy" consensus rating with …

Twist Bioscience (TWST): ARK Investment Management reports 4.55M-share, 7.31% stake

ARK Investment Management LLC and its founder Catherine D. Wood have reported a beneficial ownership of 4,549,803 shares of Twist Bioscience Corp (TWST) common stock, representing 7.31% of the company's class. The filing, a Schedule 13G/A, indicates that ARK has sole voting power over …

Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake

Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake

Cormorant Asset Management, LP and Bihua Chen have reported a significant ownership stake of 9.17% in Bright Minds Biosciences Inc. This beneficial ownership translates to 900,000 Common Shares out of 9,812,061 shares outstanding as of May 15, 2026. The reporting persons share voting and …

Die Edwards-Lifesciences-Aktie steigt dank starker Q2-Dynamik und hoher Bewertung

TMC Life Sciences Berhad Declares First and Final Single-Tier Dividend in Respect of the Financial Year Ended 30 June 2026

Gilead wins appeals court ruling against overseas drug imports

A federal appeals court has upheld a preliminary injunction preventing companies from importing international versions of Gilead's HIV drug Biktarvy into the U.S. and distributing them via employer health plans. The court ruled that the overseas versions materially differ from FDA-regulated U.S. versions, highlighting …

Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement

Daré Bioscience has announced a definitive securities purchase agreement with institutional investors for a registered direct offering, expecting to raise approximately $6.0 million. The offering includes the sale of about 4.38 million shares of common stock at $1.37 per share, along with concurrent private …

Kodiak Sciences (NASDAQ:KOD) Shares Gap Down - Time to Sell?

Kodiak Sciences (NASDAQ:KOD) shares gapped down before Friday's market open, though they later recovered some ground. The clinical-stage biopharmaceutical company, which focuses on retinal disease treatments, reported a quarterly loss that missed analyst estimates. Despite the earnings miss, analyst sentiment is generally positive, with …

Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8

Citi has reiterated its Buy rating for Caribou Biosciences (CRBU.US) and maintained its target price at $8. This indicates the firm's continued positive outlook on the company's stock performance.

Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 9.99% in Cellectar Biosciences Inc. Class A Common Stock, totaling 851,285 shares. This disclosure, made via a SCHEDULE 13G SEC filing, indicates shared voting and dispositive power over these shares. The …

Twist Bioscience (NASDAQ:TWST) Trading Down 4.3% - Here's What Happened

Eurofins Scientific SE: Analyse Fondamentale et Notations Financières | ERF | FR0014000MR3

Kingfa Science & Technology Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Scienture Holdings Q2 non-GAAP EPS of -$0.07, revenue of $0.34M

* Scienture Holdings, Inc. press release [https://seekingalpha.com/pr/20619685-scienture-reports-q2-2026-results-with-approximately-510-percent-sequential-revenue-growth] (SCNX [https://seekingalpha.com/symbol/SCNX]): Q2 Non-GAAP EPS of -$0.07. * Revenue of $0.34M. * Net loss for Q2 2026 narrowed 58% YoY to $2.82M from $6.72M in Q2 2025. * Gross profit was $0.34M with a gross margin of …

Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake

An investor, Laurence W. Lytton, and the Lytton-Kambara Foundation have each reported a 4.99% beneficial ownership stake in Aytu BioPharma (AYTU), according to a recent Schedule 13G/A filing. Each party beneficially owns 545,946 shares, consisting of common stock and warrants, with all voting and …